[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters to the Editor
August 2007


Arch Gen Psychiatry. 2007;64(8):978. doi:10.1001/archpsyc.64.8.978-a

The Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)1 of the relative effectiveness of first (FGA)- and second (SGA)-generation antipsychotic treatments of schizophrenia reports negative findings, concluding that “there is no disadvantage across 1 year . . . in using FGAs. . . . ”1(p1079) In one commentary,2 Lieberman calls the findings of CUtLASS and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study “virtually identical,” clearly referring to what he calls the “sobering”2(p1071) conclusion that “these studies found few differences in effectiveness between first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). . . . ”2(p1069) In another commentary,3 Rosenheck writes that CUtLASS “echoes” CATIE, which “similarly, found no significant differences in time to all-cause discontinuation, the primary outcome. . . . ”2(p1075)

First Page Preview View Large
First page PDF preview
First page PDF preview